References
- Simonneau G, Galié N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5-12S
- Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-38
- Humbert M, Sitbon O, Simmoneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36
- Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65
- Frost AE, Badesch DB, Barst RJ, et al. A comparison of REVEAL registry demographic data with other/prior registries of pulmonary arterial hypertension (PAH). Chest Meeting Abstracts 2008;134:p134001
- Badesch DB, Abman SH, Simmoneau G, et al. Medical therapy for pulmonary arterial hypertension. Updated ACCP Evidence-Based Clinical Practice Guidelines. Chest 2007;131:1917-28
- Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-10
- Enright PL. The six-minute walk test. Respir Care 2003;48:783-85
- Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-47
- Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
- Ware JEJ, Kosinski M, Gandek B. SF-36® Health Survey: Manual & Interpretation Guide, 2nd edn. Lincoln, RI: Qualitymetric, Inc, 2000
- Johnson JA, Coons SJ, Ergo A, et al. Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 1998;13:421-33
- Rabin R. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43
- Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008;5:623-30
- Pepke-Zaba J, Gilbert C, Collings L, et al. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008;133:183-9
- Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-19
- Olschewski H, Simonneau G, Galié N, et al.; for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
- Rector RS, Kubo SH, Cohn JN. Patients’ self-assessment of their congestive heart failure. Heart Fail 1987;1:198-209
- Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil for pulmonary arterial hypertension therapy. Circulation 2009 May 26 [Epub ahead of print]
- McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006;15:103-15
- Gomberg-Maitland M, Thenappan T, Rizvi K, et al. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008;27:124-30
- Meads DM, McKenna SP, Doughty N, et al. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J 2008;32:1513-19